This concept was adopted by Agios Pharmaceuticals when they began to research IDH mutations in glioma and AML [128] and then reported that cancer-associated IDH1 mutations produced 2R-HG, which they identified as an oncometabolite [62]. This evidence concerns the gene IDH2 and acute myeloid leukemia.